Graves' ophthalmopathy


Also found in: Wikipedia.

Graves' ophthalmopathy

Endocrinology A potentially disfiguring, sight-threatening condition that occurs in 25-50% of Pts with Graves' disease Clinical Gritty sensation in the eyes, diploplia, blurred vision, ↑ lacrimation, exophthalmos, extraocular muscle dysfunction, periorbital edema, lid edema, retraction, conjunctival chemosis and injection, exposure-type keratitis, photophobia. See Graves' disease.

Graves' ophthalmopathy

A severe eye disorder associated with thyroid gland dysfunction affecting mainly women in their 30s and 40s. It is an autoimmune disorder involving a massive cellular and fluid infiltration of the soft tissues of the bony orbit so that the upper eyelids are retracted, the eyeballs protuberant, eye movement limited and parts of the corneas often exposed and liable to drying. Optic nerve compression may lead to visual loss. Surgical decompression of the orbit may be necessary. See also EXOPHTHALMOS and THYROTOXICOSIS.
References in periodicals archive ?
Immunovant, a biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases and currently evaluating IMVT-1401 in patients with moderate-to-severe active Graves' ophthalmopathy (GO), announced yesterday that it has named Pete Salzmann, MD as its new chief executive officer.
Immunovant recently announced the start of dosing in ASCEND-GO 1, an open label, single-arm Phase 2a clinical trial evaluating IMVT-1401 in patients with moderate-to-severe active Graves' ophthalmopathy (GO).
Graves' ophthalmopathy is an inflammatory disease of the eye and orbital tissues, and its prevalence has been previously reported to range from 17.1-67.6% in children and adolescents with GD (21,27).
In adults, it is commonly related to Graves' ophthalmopathy, orbital pseudotumor, and rhinosinusitis-related orbital infections.
Multiple sclerosis, Graves' ophthalmopathy, Miller-Fisher syndrome, mitochondrial diseases, oculopharyngeal muscular dystrophy, vascular causes, and tumors were considered in the differential diagnosis.
Our results were in agreement with Vestergaard20 as he reported that GD patients who smoke had a 5 times higher threat of developing Graves' ophthalmopathy than those who do not smoke.
Graves' ophthalmopathy is a potentially sight-threatening disease of the orbital cavity, generally accompanied by hyperthyroidism associated with Graves' disease [1].
Thyroid-associated orbitopathy (TAO), also known as thyroid eye disease or Graves' ophthalmopathy, is an autoimmune disease affecting the thyroid, orbits, and skin.
Tanda et al., "Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study," The Journal of Clinical Endocrinology & Metabolism, vol.
Esser, "Surgical treatment of Graves' ophthalmopathy," Best Practice and Research Clinical Endocrinology and Metabolism, vol.